NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

Core Insights - Nordic Pharma, Inc. has partnered with Harrow to launch an authorized generic of Maxitrol, which treats bacterial eye infections, with annual sales of $20.8 million in the U.S. as of January 2025 [1][2]. Company Overview - Nordic Group B.V. is a medium-sized international pharmaceutical company focused on specialty products, particularly in Eye Care, Rheumatology, and Women's Health, with a strategy of targeted developments and acquisitions [3]. - Nordic Pharma, Inc. leverages partnerships with global biopharmaceutical companies to bring biotechnology-derived medicines and advanced manufacturing technologies to market [5]. Industry Context - Harrow, a leading eyecare pharmaceutical company, is dedicated to the discovery and commercialization of innovative ophthalmic products, making them accessible and affordable to millions of patients in North America [6].